Citations

Mayo Clinic

Showing 10 of 108585 citations.

Opioid analgesic use among patients presenting with acute abdominal pain and factors associated with surgical diagnoses
Khemani, Disha, Camilleri, Michael , Roldan, Ana , Nelson, Alfred D. , Zinsmeister, Alan R., Park, Seon‐Young , Acosta, Andrés

Neurogastroenterology & Motility | December 26, 2016 | Volume: 29 | Issue: 5 | Pages: No page available

10.1111/nmo.13000 | PMID 28019066 Get It

AbstractBackgroundThe prevalence of chronic opioid use among non‐cancer patients presenting with acute abdominal pain (AAP) is unknown. The aim was to characterize opioid use, constipation, diagnoses, and risk factors for surgical diagnoses among non‐cancer patients presenting with AAP to an emergency department (ED).MethodsWe performed a retrospective, observational cohort study of all (n=16,121) adult patients (88% from MN, IA and WI) presenting during 2014 with AAP. We used electronic medical records, and focused on 2352 adults with AAP who underwent abdominal CT scan within 24 hours of presentation. We determined odds ratios of association with constipation and features predicting conditions that may require surgery (surgical diagnosis).Key ResultsThere were 2352 eligible patients; 18.8% were opioid users. Constipation was more frequent in opioid (35.1%) compared to non‐opioid users [OR 2.88 (95% CI 2.28, 3.62)]. Prevalence of surgical diagnosis in the opioid and non‐opioid users was 35.3% and 41.7% respectively (P=.019). By univariate analysis, age and neutrophil count independently predicted increased risk, and chronic opioid use decreased risk of surgical diagnosis. Internal validation of logistic models using a randomly selected validation subset (25% of entire cohort, 587/2352) showed receiver operating characteristic (ROC) curves for the validation and full cohorts were similar.Conclusions and InferencesApproximately 19% of adults presenting with AAP were opioid users; constipation is almost three times as likely in opioid users compared to non‐opioid users presenting with AAP. Factors significantly associated with altered risk of surgical diagnoses were age, opioid use, and neutrophil count.
Classification of Cruciate Ligament Dysplasia and the Severity of Congenital Fibular Deficiency
Walker, Janet L. , Milbrandt, Todd A. , Iwinski, Henry J. , Talwalkar, Vishwas

Journal of Pediatric Orthopaedics | December 25, 2016 | Volume: 39 | Issue: 3 | Pages: 136-140

10.1097/bpo.0000000000000910 | PMID 28009801 Get It

Background: Dysplasia of the cruciate ligaments has been found in many patients with congenital fibular deficiency. A recent classification system has shown that radiographic tibial spine changes can predict the hypoplasia and aplasia of the cruciate ligaments. We used this radiographic classification to determine the frequency of these abnormalities and how they correlate with the severity of fibular deficiency and lateral femoral condylar hypoplasia. Methods: Using a hospital database search for fibular deficiency, 99 patients ≥6 years with unilateral fibular deficiency were identified. Existing radiographs of both knees were available for 75 patients and reviewed for the tibial spine changes and Achterman and Kalamchi classification of the fibular deficiency. Measurements of femoral condyle heights in 74 of 75 patients were recorded before any surgery to the distal femoral physis to assess lateral femoral condylar hypoplasia. Results: Twenty-two patients had hypoplasia of the lateral tibial spine+normal medial spine, 29 had absence of the lateral tibial spine+hypoplastic medial spine, and 11 had absence of both tibial spines. Five tibial spines were normal and 8 were unclassifiable. The severity of the tibial spine dysplasia, particularly absence of the lateral tibial spine, correlated with the severity of the fibular deficiency. (P<0.0001) The mean lateral femoral condylar hypoplasia, measured by involved: uninvolved lateral condyle heights, was 0.85±0.11. Those with some preservation of the lateral tibial spine had less lateral femoral condylar hypoplasia (P=0.0009). This lateral femoral condylar hypoplasia was positively associated with the severity of the fibular absence (P=0.039) and foot ray deficiency (P=0.036). Conclusions: The severity of cruciate ligament dysplasia in fibular deficiency is directly correlated with the severity of fibular absence, lateral femoral condylar hypoplasia, and the absence of foot rays. This suggests that the embryological factors involved have a complex interplay for all of these clinical findings. Level of Evidence: Level III.
Alveolar Soft Part Sarcoma of the Female Genital Tract
Schoolmeester, J. Kenneth , Carlson, Joseph W. , Keeney, Gary L., Fritchie, Karen , Oliva, Esther , Young, Robert H. , Nucci, Marisa R. , Carlson, Joseph W

American Journal of Surgical Pathology | December 25, 2016 | Volume: 41 | Issue: 5 | Pages: 622-632

10.1097/pas.0000000000000796 | PMID 28009610 Get It

Alveolar soft part sarcoma (ASPS) is a morphologically distinctive neoplasm of unknown differentiation that bears a characteristic gene fusion involving ASPSCR1 and TFE3. ASPS can occur in the female genital tract, but is rare. Eleven cases with an initial diagnosis of ASPS at female genital tract sites were evaluated for their morphologic features and immunoprofile using a panel of antibodies (TFE3, HMB45, melan-A, smooth muscle actin, desmin, and h-Caldesmon). In addition, the presence of TFE3 rearrangement and subsequent ASPSCR1-TFE3 fusion were determined by fluorescence in situ hybridization. Ten tumors retained their classification as ASPS based on their morphologic appearance, immunohistochemical profile, and demonstration of ASPSCR1-TFE3 fusion. The remaining case was reclassified as conventional-type PEComa due to its pattern of HMB45, melan-A, and desmin positivity as well as absence of TFE3 rearrangement. Sites of the 10 ASPS were uterine corpus (3), cervix (2), uterus not further specified (2), vagina (2), and vulva (1). The age of the patients ranged from 15 to 68 years (mean 34 y, median 32 y). The tumors demonstrated a spectrum of morphologic features, but all had a consistent immunophenotype of strong TFE3 nuclear expression and lack of muscle (smooth muscle actin, desmin, h-Caldesmon) and melanocytic (melan-A, HMB45) markers, except focal positivity for HMB45 in 1. Follow-up was available for 4 patients ranging from 1 to 35 months (mean 15 mo, median 25 mo) and they were alive and had no evidence of recurrence or metastasis at last follow-up. Distinguishing ASPS from its morphologic mimics, particularly PEComa, is important due to increasingly efficacious targeted agents such as MET-selective and VEGF signaling inhibitors in the former and mTOR inhibition therapy in the latter.
Perioperative and Anesthetic Considerations for Neurosurgical Laser Interstitial Thermal Therapy Ablations
Jimenez‐Ruiz, Federico , Arnold, Benjamin, Tatsui, Claudio Esteves , Cata, Juan P.

Journal of Neurosurgical Anesthesiology | December 25, 2016 | Volume: 30 | Issue: 1 | Pages: 10-17

10.1097/ana.0000000000000376 | PMID 28009635 Get It

Objective: To describe the anesthetic considerations in patients undergoing laser interstitial thermal therapy (LITT) for neurosurgical procedures. Background: LITT for neurosurgical procedures is being increasingly used in a variety of central nervous system diseases. Several studies have demonstrated promising results including a shorter hospital stay. Given the rising trend for the use of LITT, anesthesiologists need to be familiar with the anesthetic considerations to provide care for patients undergoing these types of procedures. Materials and Methods: PubMed was searched in April 2016 using different combinations of the following MeSH terms: “Central nervous System,” “laser therapy,” “Ablation Techniques,” “Anesthesia,” and “Spinal Cord Neoplasms.” A total of 54 relevant manuscripts were included in this review article. Conclusions: LITT is a promising therapeutic approach for multiple central nervous system disorders. Anesthesiologists must be familiar with the anesthetic considerations and the technical aspects of the procedure when providing care for patients undergoing LITT. The literature is scarce on the impact of different anesthesia and analgesia techniques on clinical outcomes. Therefore, studies comparing different anesthetic regimens and the impact on outcomes are needed to make relevant recommendations on the anesthesia care of these patients.
Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection
Spiceland, Clayton M. , Khanna, Sahil , Pardi, Darrell S.

Journal of Clinical Gastroenterology | December 25, 2016 | Volume: 52 | Issue: 2 | Pages: 151-154

10.1097/mcg.0000000000000769 | PMID 28009682 Get It

Background and Goals: Fidaxomicin is a new antibiotic used to treat Clostridium difficile infection (CDI). Given limited clinical experience with fidaxomicin, we assessed outcomes in a diverse cohort of patients with CDI treated with fidaxomicin. Study: All CDI cases treated with fidaxomicin at 3 referral centers over a 4-year period were included. Response was defined as resolution of diarrhea and recurrence was defined by recurrence of CDI within 8 weeks of the end of treatment. Results: Overall, 81 patients (median age 55.9 y; 53% female; 26% with inflammatory bowel disease) were included. Response occurred in 90%. Responders had fewer prior CDI episodes [median 1 (range, 0 to 8)] than nonresponders [median 2.5 (range, 1 to 8)], P =0.01. Response after a first CDI episode was 100%, 96% after 1 prior episode, and 82% after 2 or more, P =0.02. Recurrence occurred in 19%. Patients without recurrence had fewer prior episodes of CDI [median 1 (range, 0 to 6)] than patients who recurred [median 2 (range, 1 to 8)], P =0.005. Recurrence after a first episode was 0%, 23% after 1 prior episode, and 29% after 2 or more, P =0.005. All patients with inflammatory bowel disease responded either with improvement of symptoms or a negative C. difficile test; 19% recurred. Conclusions: All patients with a first CDI episode treated with fidaxomicin responded with no recurrences. Patients with prior CDI episodes were less likely to respond (especially with more than 1 prior episode) and more likely to recur, suggesting a greater clinical benefit of fidaxomicin earlier in the course of CDI.
Effect of Body Mass Index on Reoperation and Complications After Total Knee Arthroplasty
Wagner, Eric R. , Fruth, Kristin M. , Harmsen, William S. , Berry, Daniel J. , Kamath, Atul F. , Wagner, Eric R , Berry, Daniel J

Journal of Bone and Joint Surgery | December 24, 2016 | Volume: 98 | Issue: 24 | Pages: 2052-2060

10.2106/jbjs.16.00093 | PMID 28002368 Get It

Background: High body mass index (BMI) is associated with increased rates of complications after total knee arthroplasty. To date, to our knowledge, studies have examined risk as a dichotomous variable using specific BMI thresholds. The purpose of this investigation was to quantify implant survival and the risk of common complications after total knee arthroplasty using BMI as a continuous variable. Methods: Using prospectively collected data from our institutional total joint registry, we analyzed 22,289 consecutive knees, in 16,136 patients, treated with primary total knee arthroplasty from 1985 to 2012. The mean BMI of these patients at the time of the surgical procedure was 31.3 kg/m 2 (range, 11 to 69 kg/m 2 ). The Kaplan-Meier survival method was used to estimate survivorship, reoperations, and common complications, with associations of outcomes assessed using a Cox regression model. Results: Utilizing smoothing spline parameterization, we found that reoperation (p < 0.001) and implant revision or removal rates (p < 0.001) increased with increasing BMI after total knee arthroplasty. Increasing BMI also was associated with increased rates of wound infection (hazard ratio [HR], 1.07; p < 0.001) and deep infection (HR, 1.08; p < 0.001) per unit of BMI over 35 kg/m 2 . A BMI of 35 to 40 kg/m 2 was associated with a higher rate of implant revision for aseptic loosening (p < 0.001) and for polyethylene wear (p < 0.001) compared with a BMI of 18 to 24.99 kg/m 2 . There was no correlation between BMI and risk of venous thromboembolism, tibiofemoral instability, or need for knee manipulation. Conclusions: The rates of reoperation, implant revision or removal, and many common complications after total knee arthroplasty were strongly associated with BMI. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy
Koga, Shunsuke , Sánchez-Contreras, Mónica , Josephs, Keith A. , Uitti, Ryan J. , Graff‐Radford, Neill R. , Gerpen, Jay A. van, Cheshire, William P. , Rademakers, Rosa , Van Gerpen, Jay A, Wszołek, Zbigniew K. , Dickson, Dennis W. , Koga, Shunsuke , Cheshire, William P , Sanchez-Contreras, Monica

Movement Disorders | December 24, 2016 | Volume: 32 | Issue: 2 | Pages: 246-255

10.1002/mds.26809 | PMID 28009087 Get It

ABSTRACTBackgroundThis study aimed to determine the frequency of transactive response DNA binding protein 43 kDa pathology in PSP, the clinical features of patients with this pathology, and genetic risk factors for it.MethodsHippocampal sections were screened with immunohistochemistry for transactive response DNA binding protein 43 kDa in 945 PSP cases. A subset of 261 cases that were negative in hippocampus was screened in the amygdala. The density and disruption of this pathology, as well as regional tau burden, and clinical and genetic characteristics were analyzed.ResultsWe observed transactive response DNA binding protein 43 kDa pathology in 47 cases in the hippocampus and an additional 9 cases that only affected the amygdala. Hippocampal sclerosis was the strongest risk factor, followed by Alzheimer's disease pathology, argyrophilic grain disease, and older age at death. Five stages of transactive response DNA binding protein 43 kDa pathology were identified in PSP: Stage A had pathology only in the amygdala (16%); stage I had pathology confined to the hippocampus and entorhinal cortex (9%); stage II included both regions of stage A and I (38%); stage III spread further to medial occipitotemporal gyrus (20%); and stage IV had pathology in the dorsolateral frontal lobe (18%). Anatomical areas vulnerable to PSP pathology had varying degrees of this pathology in stage II and later. PSP with transactive response DNA binding protein 43 kDa pathology were older at disease onset and had lower median MMSE scores; however, the latter was driven by concurrent pathologies.ConclusionsDistribution and clinical characteristics of transactive response DNA binding protein 43 kDa pathology in PSP were influenced by concurrent pathologies. This is the first study to observe that PSP‐vulnerable regions are also susceptible to this non‐tau pathology. © 2016 International Parkinson and Movement Disorder Society.
Salpingo-oophorectomy at the Time of Benign Hysterectomy: A Systematic Review
Rocca, Walter A. , Stewart, Elizabeth A. , Miller, Virginia M. , Faubion, Stephanie S. , Stewart, E A

Obstetrics & Gynecology | December 24, 2016 | Volume: 129 | Issue: 1 | Pages: 202-203

10.1097/aog.0000000000001828 | PMID 28002288 Get It

Outcomes of surgically treated human papillomavirus–related oropharyngeal squamous cell carcinoma with N3 disease
Zenga, Joseph , Haughey, Bruce H. , Jackson, Ryan S. , Chrisinger, John S.A. , Bhatt, Neel K. , Martin, Eliot J., Moore, Eric J. , Paniello, Randal C., Rich, Jason T. , Adkins, Douglas R. , Gay, Hiram A. , Kallogjeri, Dorina , Thorstad, Wade , Nussenbaum, Brian A. , Chrisinger, John S A

The Laryngoscope | December 24, 2016 | Volume: 127 | Issue: 9 | Pages: 2033-2037

10.1002/lary.26455 | PMID 28008626 Get It

Objectives/HypothesisTo evaluate outcomes for patients with pathological N3 (pN3) neck disease from human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma (OPSCC) and determine variables predictive of survival.Study DesignRetrospective case series with chart review.MethodsThis study was conducted between 1998 and 2013 and included patients with HPV‐related OPSCC treated with surgery with or without adjuvant therapy and who had pN3 nodal disease. The primary outcome was disease‐specific survival (DSS). Secondary outcomes included overall survival (OS), disease‐free survival (DFS), adverse events, and gastrostomy tube rates.ResultsThirty‐nine patients were included, of whom 36 (90%) underwent adjuvant therapy. Median follow‐up was 39 months (range, 2–147 months). Mean age was 56 years, and 87% were male. Seventeen patients (44%) underwent selective neck dissection, whereas six (15%) underwent radical (n = 2) or extended radical (n = 4) neck dissection. Ninety‐two percent had extracapsular extension. Five‐year Kaplan‐Meier estimated DSS, OS, and DFS were 89% (95% confidence interval [CI]: 79%–99%), 87% (95% CI: 75%–99%), and 84% (95% CI: 72%–96%), respectively. The disease recurrence rate was 10% (5% regional, 5% distant metastasis). Patients with less than 5 pathologically positive lymph nodes (P = .041) had improved DFS.ConclusionsPatients with HPV‐related OPSCC and pN3 nodal disease treated with surgery and adjuvant therapy have very favorable long‐term survival and regional control. Patients with five or more pathologically positive lymph nodes may be at higher risk for recurrence.Level of Evidence4. Laryngoscope, 127:2033–2037, 2017
Dynamics of pulse wave velocity and vascular augmentation index in association with endothelial progenitor cells in SLE
Korsten, Peter , Patschan, Daniel , Henze, Elvira , Niewold, Timothy B. , Müller, Gerhard A. , Patschan, Susann , Korsten, Peter

Lupus Science & Medicine | December 24, 2016 | Volume: 3 | Issue: 1 | Pages: e000185

10.1136/lupus-2016-000185 | PMID 28176918 Get It

Patients with SLE display a significantly higher cardiovascular risk (CVR). Pulse wave velocity (PWV) has meanwhile been established as a reliable parameter of end-organ damage. Endothelial progenitor cells (EPCs) are critically involved in vascular repair under both physiological and pathological conditions. The aim of the study was to analyse PWV and the Vascular Augmentation Index (VAI) and EPC numbers/regeneration in a well-defined German SLE cohort. Thirty patients were included. Only two individuals displayed a PWV of above 10 m/s. There was no correlation between PWV percentiles and disease activity as reflected by the SLE Disease Activity Index. Neither EPC colonies nor percentages of circulating EPCs (CD133+/KDR+) correlated with PWV/VAI in a positive or negative manner. Thus, it can be questioned whether pulse wave analysis and/or EPC proliferation and circulating cell numbers are truly useful for CVR assessment in SLE.